Valuation dashboard for NeurAxis, Inc. (NRXS) with P/E N/A, P/B 12.38, EV/EBITDA -8.76 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics.
Analysis Summary
NeurAxis, Inc. reported revenue of $3.6M in the most recent fiscal year, growing at a 5-year CAGR of 13.1%.
Trailing-twelve-month margins: gross margin 85.6%, operating margin -144.5%, net margin -148.0%.
At the current price of $6.94, NRXS has negative trailing earnings (P/E not meaningful) and an ROE of -173.28%. Market capitalisation stands at $87M.
Balance sheet quality for NRXS: current ratio of 2.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 12.38 |
| EV / EBITDA | -8.76 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NRXS | NeurAxis, Inc. | $87M | 12.38 | -173.3% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $6.94 |
| Market Cap | $87M |
| Exchange | AMEX |
| Country | US |
Profitability
| Return on Equity | -173.28% |
| Return on Invested Capital | -109.52% |
| Return on Assets | -78.73% |
| Gross Margin | 85.56% |
| Operating Margin | -144.51% |
| Net Margin | -148.04% |
Related companies: CLGN · CVKD · ENLV · KLTO · NERV · NRSN · RLYB
Explore sector: Healthcare · Biotechnology
More sections of NRXS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks